The skin immune system and the challenge of tumour immunosurveillance

European Journal of Dermatology

Volumn 15, Issue 2, 2005, Pages 63-69

  Woods, Gregory M ^a   Malley, Roslyn C ^a   Muller, H Konrad ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Dendritic cells; Immunosurveillance; Langerhans cells; Skin immune system; Tumours

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD1 ANTIGEN; CD11 ANTIGEN; CD33 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; COLONY STIMULATING FACTOR 1; CYTOKINE; DIMETHYLBENZ[A]ANTHRACENE; FAS ANTIGEN; FAS LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; HLA G ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LECTIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN; PROTEIN P53; PROTEIN S 100; RANTES; STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BASAL CELL CARCINOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOCYTOSIS; ENDOTHELIUM CELL; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; KERATINOCYTE; LANGERHANS CELL; MAST CELL; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PINOCYTOSIS; REVIEW; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR REGRESSION; ULTRAVIOLET B RADIATION;

ANIMALS; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC SURVEILLANCE; LANGERHANS CELLS; SKIN; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 15944403227     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Bos JD. Skin Immune System (SIS). 3rd ed. Boca Raton, Florida: CRC Press, 2004.
2. Bos JD, Kapsenberg ML. The skin immune system. Its cellular constituents and their interactions. Immunol Today 1986; 7: 235-40.
3. Streilein JW, Lonsberry LW, Bergstresser PR. Depletion of epidermal Langerhans cells and Ia immunogenicity from tape-stripped mouse skin. J Exp Med 1982; 155: 863-71.
4. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
5. Marshall V. Premalignant and malignant skin tumours in immunosuppressed patients. Transplantation 1974; 17: 272-5.
6. Muller HK, Halliday GM, Woods GM. The skin immune system and tumor immunosurveillance. In: Bos JD, ed. Skin Immune System (SIS). 3rd ed. Boca Raton, Florida: CRC Press, 2004: 475-96.
7. Muller HK, Bucana CD, Kripke ML. Antigen presentation in the skin: modulation by u.v. radiation and chemical carcinogens. Semin Immunol 1992; 4: 205-15.
8. Chu AC, Morris B. The keratinocyte. In: Bos JD, ed. Skin Immune System (SIS). 3rd ed. Boca Raton, Florida: CRC, 2004: 77-100.
9. Steinhofr M, Luger TA. The skin cytokine network. In: Bos JD, ed. Skin Immune System. 3rd ed. Boca Raton, Florida: CRC, 2004: 349-72.
10. Van Loveren H, Redegeld F, Matsuda H, Buckley T, Teppema JS, Garssen J. Mast Cells. In: Bos JD, ed. Skin Immune System (SIS). 2nd Ed. Boca Raton, Florida: CRC, 1991: 159-84.
11. Galli SJ. New concepts about the mast cell. N Engl J Med 1993; 328: 257-65.
12. Breathnach SM. Origin, cell lineage, ontogeny, tissue distribution and kinetics of Langerhans cells. In: Schuler G, ed. Epidermal Langerhans Cells. Boca Raton: CRC Press Inc, 1991: 23-48.
13. Katz SI, Tamaki K, Sachs DH. Epidermal Langerhans cells are derived from cells ariqinating in bone marrow. Nature 1979; 282: 324-6.
14. Frelinger JG, Hood L, Hill S, Frelinger JA. Mouse epidermal Ia molecules nave a bone marrow origin. Nature 1979; 282: 321-3.
15. Perreault C, Pelletier M, Landry D, Gyger M. Study of Langerhans cells after allogeneic bone marrow transplantation. Blood 1984; 63: 807-11.
16. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245-87.
17. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, Charo I, et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 2002; 3: 1135-41.
18. Romani N, Holzmann S, Tripp CH, Koch F, Stoitzner P. Langerhans cells-dendritic cells of the epidermis. APMIS 2003; 111: 725-40.
19. Teunissen MB. Langerhans cells and other skin dendritric cells. In: Bos JD, ed. Skin Immune System (SIS). 3rd ed. Boca Raton, Florida: CRC Press, 2004: 123-82.
20. Valladeau J, Dezutter-Dambuyant C, Saeland S. Langerin/CD207 sheds light on formation of Birbeck granules and their possible function in Langerhans cells. Immunol Res 2003; 28: 93-107.
21. Watts C, Marsh M. Endocytosis: what goes in and how? J Cell Sci 1992; 103: 1-8.
22. Swanson JA, Watts C. Macropinocytosis. Trends Cell Biol 1995; 5: 424-8.
23. Kato M, Neil TK, Clark GJ, Morris CM, Sorg RV, Hart DNJ. cDNA cloning of human DEC-205, a putative antigen-uptake receptor on dendritic cells. Immunogenetics 1998; 47: 442-50.
24. Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y, et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000; 12: 71-81.
25. Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM. Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 1996; 157: 541-8.
26. Esposito-Farese ME, Sautes C, De la Salle H, Latour S, Bieber T, De la Salle C, et al. Membrane and soluble Fc gamma RII/III modulate the antigen-presenting capacity of murine dendritic epidermal Langerhans cells for IgG-complexed antigens. J Immunol 1995; 155: 1725-36.
27. Reis S, Stahl PD, Austyn JM. Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med 1993; 178: 509-19.
28. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999; 17: 593-623.
29. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000; 105: 497-504.
30. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogowa T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999; 11: 443-51.
31. Romani N, Koide S, Crowley M, Witmer-Pack M, Livingstone AM, Fathman CG, et al. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented test by immature, epidermal Langerhans cells. J Exp Med 1989; 169: 1169-78.
32. Heath WR, Carbone FR. Cytotoxic T lymphocyte activation by cross-priming. Curr Opin Immunol 1999; 11: 314-8.
33. Cumberbatch M, Dearman RJ, Griffiths CE, Kimber I. Epidermal Langerhans cell migration and sensitisation to chemical allergens. APMIS 2003; 111: 797-804.
34. Jakob T, Ring J, Udey MC. Multistep navigation of Langerhans/dendritic cells in and out of the skin. J Allergy Clin Immunol 2001; 108: 688-96.
35. Ratzinger G, Stoitzner P, Ebner S, Lutz MB, Layton GT, Rainer C et al. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol 2002; 168: 4361-71.
36. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
37. Picker LJ. Control of lymphocyte homing. Curr Opin Immunol 1994; 6: 394-406.
38. Morales J, Homey B, Vicari AP, Hudak S, Oldham E, Hedrick J, et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA 1999; 96: 14470-5.
39. Saint-Mezard P, Krasteva M, Berard F, Dubois B, Kaiserlian D, Nicolas JF. Allergic Contact Dermatitis. In: Bos JD, ed. Skin Immune System (SIS). Boca Raton, Florida: CRC Press, 2004: 593-614.
40. Kripke ML, Fisher MS. Immunologic parameters of ultraviolet carcinogenesis. J Natl Cancer Inst 1976; 57: 211-5.
41. Macatonia SE, Edwards AJ, Knight SC. Dendritic cells and the initiation of contact sensitivity to fluorescein isothiocyanate. Immunology 1986; 59: 509-14.
42. Woods GM, Doherty KV, Malley RC, Rist MJ, Muller HK. Carcinogen-modified dendritic cells induce immunosuppression by incomplete T-cell activation resulting from impaired antigen uptake and reduced CD86 expression. Immunology 2000; 99: 16-22.
43. Kripke ML. T cell suppressors in ultraviolet carcinogenesis. Transplant Proc 1974; 16: 474-5.
44. Halliday GM, Muller HK. Sensitization through carcinogen induced Langerhans cell deficient skin activates long lived suppressor cells for both cellular and humoral immunity. Cell Immunol 1987; 109: 206-21.
45. Dandie GW, Clydesdale GJ, Radcliff FJ, Muller HK. Migration of Langerhans cells and gammadelta dendritic cells from UV-B-irradiated sheep skin. Immunol Cell Biol 2001; 79: 41-8.
46. Woods GM, Qu M, Ragg SJ, Muller HK. Chemicol carcinogens and antigens induce immune suppression via Langerhans' cell depletion. Immunology 1996; 88: 134-9.
47. Ragg SJ, Woods GM, Egan PJ, Dandie GW, Muller HK. Failure of carcinogen-altered dendritic cells to initiate T cell proliferation is associated with reduced IL-1 beta secretion. Cell Immunol 1997; 178: 17-23.
48. Muller HK, Bucana CD, Kripke ML, Cox PA, Saijo S, Strickland FM. Ultraviolet irradiation of murine skin alters cluster formation between lymph node dendritic cells and specific T lymphocytes. Cell Immunol 1994; 157: 263-76.
49. De Fabo EC, Noanan FP. Mechanism of immune suppression by ultraviolet irradiation in vivo. J Exp Med 1983; 157: 84-98.
50. Rivas JM, Ullrich SE. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol 1992; 149: 3865-71.
51. Khalil Z, Townley SL, Grimbaldeston MA, Finlay-Jones JJ, Hart PH. cis-Urocanic acid stimulates neuropeptide release from peripheral sensory nerves. J Invest Dermatol 2001; 117: 886-91.
52. Townley SL, Grimbaldeston MA, Ferguson I, Rush RA, Zhang SH, Zhou XF, et al. Nerve growth factor, neuropeptides, and mast cells in ultraviolet-B-induced systemic suppression of contact hypersensitivity responses in mice. J Invest Dermatol 2002; 118: 396-401.
53. Fairley GH, Lewis MG, Ikonopisov RL, Nairn RC, Alexander P. Detection of tumor specific immune reactions in human melanoma. Ann N Y Acad Sci 1971; 177: 286-9.
54. Noirn RC, Guli EP, Nind AP, Muller HK, Rolland JM, Minty CC. Specific immune response in human skin carcinoma. BMJ 1971; 4: 701-5.
55. Curson C, Weedon D. Spontaneous regression in basal cell carcinomas. J Cutan Pathol 1979; 6: 432-7.
56. McGovern VJ. Spontaneous regression of melanoma. Pathology 1975; 7: 91-9.
57. Urosevic M, Dummer R. Immunotherapy for nonmelanoma skin cancer: does it have a future? Cancer 2002; 94: 477-85.
58. Melnikova VO, Bolshakov SV, Walker C, Ananthaswamy HN. Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. Oncogene 2004; 23: 2347-56.
59. Halliday GM. Skin immunity and melanoma development. In: Thompson JF, Morton DL, Kroon BBR, eds. Textbook of Melanoma. London: Martin Dunitz Publications, 2004: 25-42.
60. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001; 61: 5544-51.
61. Storkus WJ, Zeh HJ, Maeurer MJ, Salter RD, Lotze MT. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 1993; 151: 3719-27.
62. Slingluff Jr. CL, Cox AL, Henderson RA, Hunt DF, Engelhard VH. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J Immunol 1993; 150: 2955-63.
63. Degiovanni G, Hainaut P, Lahaye T, Weynants P, Boon T. Antigens recognized on a melanoma cell line by autologous cytolytic T lymphocytes are also expressed on freshly collected tumor cells. Eur J Immunol 1990; 20: 1865-8.
64. Palmowski M, Salio M, Dunbar RP, Cerundolo V. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Immunol Rev 2002; 188: 155-63.
65. Black AP, Ogg GS. The role of p53 in the immunobiology of cutaneous squamous cell carcinoma. Clin Exp Immunol 2003; 132: 379-84.
66. McArdle JP, Muller HK. Quantitative assessment of Langerhans' cells in human cervical intraepithelial neoplasia and wart virus infection. Am J Obstet Gynecol 1986; 154: 509-15.
67. Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003; 200: 255-68.
68. Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993; 25: 338-43.
69. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999; 190: 1417-26.
70. Halliday GM, Le S. Transforming growth factor-beta produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. Int Immunol 2001; 13: 1147-54.
71. Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 1997; 108: 14-9.
72. Hunt MJ, Halliday GM, Weedon D, Cooke BE, Barnetson RS. Regression in basal cell carcinoma: an immunohistochemical analysis. Br J Dermatol 1994; 130: 1-8.
73. Wong DA, Bishop GA, Lowes MA, Cooke B, Barnetson RS, Halliday GM. Cytokine profiles in spontaneously regressing basal cell carcinomas. Br J Dermatol 2000; 143: 91-8.
74. Boon T, Gajewski TF, Coulie PG. From defined human tumor antigens to effective immunization. Immunol Today 1995; 16: 334-5.
75. Ugurel S, Reinhold U, Tilgen W. HLA-G in melanoma: A new strategy to escape from immunosurveillance? Onkologie 2002; 25: 129-34.
76. Owen-Schaub LB, Van Golen KL, Hill LL, Price JE. Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med 1998; 188: 1717-23.
77. Ferrarini M, Imro MA, Sciorati C, Heltai S, Protti MP, Pellicciari C et al. Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes. Int J Cancer 1999; 81: 573-9.
78. Chen QY, Doniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994; 56: 755-60.
79. Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol 1994; 153: 1674-86.
80. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32.
81. Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R, Granstein RD. Tumor antigen presentation by murine epidermal cells. J Immunol 1991; 146: 3656-61.